Renal Denervation (RDN) 2024 in Austria

The following addresses health care professionals only. Conclusions and considerations have to be checked by reading the scientific references given below:

In the latest issue of Wiener Klinische Wochenschrift recommendations are provided regarding the experiences and competencies of RDN centers, as well as how multidisciplinary hypertension teams should asess indications and organize patient follow-up. This consensus paper is endorsed by the Austrian Society of Nephrology and the Working Group of Interventional Cardiology of the Austrian Society of Cardiology. Among the specific capabilities required for patient work-up, centers "should have on-site vascular surgery and a coronary/intensive care unit". Starting in 2025, RDN procedures in Austria will be reimbursed in these centers. The key foundations for this important step for RDN in Austria include the 2023 ESH guidelines, the premarket FDA approval on Nov 8th 2023 for the ultrasound-based system, and the approval in November 17th 2023 for the radiofrequency-based system, and recently the 2024 ESC guidelines. RDN has been proven to be safe and effective, offering a third treatment option alongside lifestyle changes and antihypertensive drugs in patients with resistant hypertension.
MLM medtech GmbH is proud to be actively involved in the launch of the uRDN system in Austria.